Proteomic analysis reveals LRPAP1 as a key player in the micropapillary pattern metastasis of lung adenocarcinoma

Yan，Hao jie1,2,3; Lin，Sheng cheng5; Xu，Shao hang6; Gao，Yu biao1,3; Zhou，Bao jin7; Zhou，Ruo6; Chen，Fu ming1,3; Li，Fu rong1,3,4

2024-01-15

10.1016/j.heliyon.2023.e23913

Heliyon   影响因子和分区

2405-8440

Objectives: Lung adenocarcinomas have different prognoses depending on their histological growth patterns. Micropapillary growth within lung adenocarcinoma, particularly metastasis, is related to dismal prognostic outcome. Metastasis accounts for a major factor leading to mortality among lung cancer patients. Understanding the mechanisms underlying early stage metastasis can help develop novel treatments for improving patient survival. Methods: Here, quantitative mass spectrometry was conducted for comparing protein expression profiles among various histological subtypes, including adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive adenocarcinoma (including acinar and micropapillary [MIP] types). To determine the mechanism of MIP-associated metastasis, we identified a protein that was highly expressed in MIP. The expression of the selected highly expressed MIP protein was verified via immunohistochemical (IHC) analysis and its function was validated by an in vitro migration assay. Results: Proteomic data revealed that low-density lipoprotein receptor-related protein–associated protein 1 (LRPAP1) was highly expressed in MIP group, which was confirmed by IHC. The co-expressed proteins in this study, PSMD1 and HSP90AB1, have been reported to be highly expressed in different cancers and play an essential role in metastasis. We observed that LRPAP1 promoted lung cancer progression, including metastasis, invasion and proliferation in vitro and in vivo. Conclusion: LRPAP1 is necessary for MIP-associated metastasis and is the candidate novel anti-metastasis therapeutic target.

LRPAP1 Lung adenocarcinomas Metastasis Micropapillary Proteomics

SCI

英语

第一

2-s2.0-85180596952

Scopus

1.Translational Medicine Collaborative Innovation Center,Shenzhen People's Hospital (The Second Clinical Medical College,Jinan University,The First Affiliated Hospital,Southern University of Science and Technology),Shenzhen,518020,China
2.Post-doctoral Scientific Research Station of Basic Medicine,Jinan University,Guangzhou,510632,China
3.Guangdong Engineering Technology Research Center of Stem Cell and Cell Therapy,Shenzhen Key Laboratory of Stem Cell Research and Clinical Transformation,Shenzhen Immune Cell Therapy Public Service Platform,Shenzhen,518020,China
4.Institute of Health Medicine,Southern University of Science and Technology,Shenzhen,518055,China
5.Department of Thoracic Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen,518172,China
6.Deepxomics Co.,Ltd,Shenzhen,518112,China
7.Experiment Center for Science and Technology,Shanghai University of Traditional Chinese Medicine,Shanghai,201203,China

Yan，Hao jie,Lin，Sheng cheng,Xu，Shao hang,et al. Proteomic analysis reveals LRPAP1 as a key player in the micropapillary pattern metastasis of lung adenocarcinoma[J]. Heliyon,2024,10(1).

Yan，Hao jie.,Lin，Sheng cheng.,Xu，Shao hang.,Gao，Yu biao.,Zhou，Bao jin.,...&Li，Fu rong.(2024).Proteomic analysis reveals LRPAP1 as a key player in the micropapillary pattern metastasis of lung adenocarcinoma.Heliyon,10(1).

Yan，Hao jie,et al."Proteomic analysis reveals LRPAP1 as a key player in the micropapillary pattern metastasis of lung adenocarcinoma".Heliyon 10.1(2024).